Metabolic syndrome and the risk of chronic kidney disease

O.O. Melnyk

Abstract


Metabolic syndrome (MS) is a combination of a disorder of carbohydrate metabolism, abdominal obesity, dyslipidemia and arterial hypertension. Studies show that there is a close relationship between MS and chronic kidney disease (CKD). Patients with MS have a 2.5-fold higher risk of CKD. Factors of CKD development in the metabolic syndrome are an increased level of insulin and insulin resistance, active forms of oxygen, inflammatory mediators, biologically active substan­ces, hormones, inflammatory cytokines, an increase in the activity of coagulation factors, inhibition of the fibrinolytic system. Pathological abnormalities in the kidneys in patients with MS are manifested by microvascular tubular atrophy, interstitial fibrosis and global or segmental sclerosis. Microalbumin is an early marker for MS.

Keywords


chronic kidney disease; metabolic syndrome; insulin resistance; obesity; dyslipidemia; arterial hypertension

References


Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9. PMID: 11790215.

Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome, Lancet. 2010 Jan 16;375(9710):181-3. doi: 10.1016/S0140-6736(09)61794-3.

Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. The Lancet. 2005 16 April;365(9468):1398-1405. doi: 10.1016/S0140-6736(05)66375-1.

Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745-9. PMID: 16249550.

Crepaldi G, Maggi Stefania. The metabolic syndrome: a historical context. Diabetes Voice. 2006;51:8-10.

Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008 Dec;29(7):777-822. doi: 10.1210/er.2008-0024.

Paulescu N. Traité de Physiologie Médicale. Vol. 2. Bucharest: Cartea Românească; 1920.

Kylin E. Hypertension-hyperglycemia-hyperuricemia syndrome. Zentralblatt fur Innere Medizin; 1923. p. 44.

Vague J. La difff´erenciacion sexuelle, facteur d´eterminant des formes de l’ob´esit´e. La Presse M´edicale;1947;30:339-40.

Moga A, Orha I, Stăncioiu N, Vlaicu R. Cardiopatiile cronice majore. Factori de risc şi perioada de constituire. Bucureşti: Academiei Române; 1974.

Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988 December;37(12):1595-1607. doi: 10.2337/diab.37.12.1595.

World Health Organization, Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, 1999. Available from: http://apps.who.int/iris/handle/10665/66040.

International Diabetes Federation Epidemiology Task Force Consensus Group. The IDF Consensus worldwide definition of the metabolic syndrome. International Diabetes Federation Brussels: 2005. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct; 120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644.

Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med. 2004 Feb 3;140(3):167-74. PMID: 14757614.

Chen J, Gu D, Chen CS, Wu X, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007 Apr:22 (4):1100-6. doi: 10.1093/ndt/gfl759.

Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Journal of the American Society of Nephrology. 2005;16(7):2134–40. PMID: 15901764. doi: 10.1681/ASN.2005010106.

Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. American Journal of Kidney Diseases. 2006;48(3):383-391. PMID: 16931211. doi: 10.1053/j.ajkd.2006.06.003.

Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertension Research. 2007;30(10):937-43. PMID: 18049025. doi: 10.1291/hypres.30.937.

Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinology and Metabolism Clinics of North America. 2004;33(2):417-29. PMID: 15158527. doi: 10.1016/j.ecl.2004.03.007.

Mathew A, Okada S, Sharma K. Obesity related kidney disease. Current Diabetes Reviews. 2011;7(1):41-9. PMID: 21067508.

Shulman GI. Cellular mechanisms of insulin resistance. Journal of Clinical Investigation. 2000 Jul 15;106(2):171-6. PMID: 10903330. doi: 10.1172/JCI10583.

Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. 2001;24(3):588-97. PMID: 11289486.

Kubo M, Kiyohara Y, Kato I, et al. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney International. 1999;55(6):2450-6. doi: 10.1046/j.1523-1755.1999.00458.x.

Sarafidis PA, Ruilope L.M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. American Journal of Nephrology. 2006;26(3):232-44. PMID: 16733348. doi: 10.1159/000093632.

Perlstein TS, Gerhard-Herman M, Hollenberg NK, et al. Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects. J Am Soc Nephrol 2007;18:944-51. doi: 10.1681/ASN.2006091026.

Khamaisi M, Flyvbjerg A, Haramati Z, et al. Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin-like growth factor 1 system in mild streptozotocin diabetes. Int J Exp Diab Res. 2002;3:257-64. doi: 10.1080/15604280290014008.

Wang S, DeNichilo M, Brubaker C, Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 2001;60:96-105. PMID: 11422741. doi: 10.1046/i.1523-1755.2001.00776.x.

Sowers JR. Metabolic risk factors and renal disease. Kidney International. 2007;71(8):719-20. doi: 10.1038/si.ki.5002006.

Villareal DT, Apovian CM, Kushner RF, Klein S.Obesity in older adults: Technical review and position statement of the American Society for Nutrition and NAASO, the Obesity Society. American Journal of Clinical Nutrition. 2005;82:923-34. PMID: 16280421.

Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013; 9(2):191-200. doi: 10.5114/aoms.2013.33181.

Pan SY, DesMeules M, Morrison H, Wen SW. Obesity, high energy intake, lack of physical activity, and the risk of kidney cancer. Cancer Epid Biom Prev. 2006;15:2453-60. doi: 10.1158/1055-9965.EPI-06-0616.

Srivastava T. Nondiabetic consequences of obesity on kidney. Pediatr Nephrol 2006;21:463-70. PMID: 16491417. doi: 10.1007/s00467-006-0027-4.

Rutkowski P, Klasen A, Sebekova K. Renal disease in obesity. The need for greater attention. J Ren Nutr. 2006;16(3):216-33. doi: 10.1053/i.im.2006.04.017.

Chertow GM, Hsu C, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol. 2006;17:1501-2. doi: 10.1681/ASN/2006040327.

Mathew AV, Okada S, Sharma K. Obesity related kidney disease. Curr Diabetes Rev. 2011;7(1):41-9. PMID: 21067508.

Eknoyan G. Obesity and chronic kidney disease. Nefrologia 2011;31(4):397-403. doi: 10.3265/Nefrologia.pre2011.May.10963.

Praga M. Obesity-a neglected culprit in renal disease. Nephrol Dial Transpl. 2002;17(7):1157-9. PMID: 12105233.

Iseki K, Ikenuya Y, Kinjo K. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870-9. doi: 10.1111/j.1523-1755.2004.00582.x.

Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-8. PMID: 16389251.

Sjerblad E, Fored CM, Lindbald P. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695-702. doi: 10.1681/ASN.2005060638.

Praga M, Hernandez E, Morales E, Campos AP, Valero MA, Martinez MA, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2001 Sep;16(9): 1790-8. PMID: 11522860.

Jennet J, Olson J, Schwartz M, Silva F. Heptinstall’s pathology of the kidney. Baltimore: Lippincott Williams & Wilkins; 2007. 386 p.

Kambham N, Markowitz G, Valeri A, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney International. 2001;59(4):1498-509. PMID: 11260414. doi: 10.1046/j.1523-1755.2001.0590041498.x.

Myers MG Jr, Munzberg H, Leinninger GM, Leshan RL. The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab. 2009 Feb;9(2):117-23. doi: 10.1016/i.cmet.2008.12.001.

Vanholder R, de Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. PMID: 12675874. doi: 10.1046/j.1523-1755.2003.00924.x.

Lee MC, Lee CJ, Ho GJ, et al. Hyperleptinemia positively correlated with metabolic syndrome in renal transplant recipients. Clin Transplant. 2010 Jul-Aug;24(4):124-9. PMID: 20236136. doi: 10.1111/j.1399-0012.2010.01215.x.

Stenvinkel P, Heimburger O, Lonnqvist F. Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol Dial Transplant. 1997;12:1321-5. PMID: 9249764.

Bueno de Oliveira R, Liabeuf S, Okazaki H, et al. The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. Clin Kidney J. 2013;6(1):63-70. doi: 10.1093/ckj/sfs176.

Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes. 2001 Oct;50(10):2199-202. PMID: 11574398.

Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003 Oct;88(10):4848-56. doi: 10.1210/ic.2003-030519.

Won JC, Park CY, Lee WY, et al. Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. J Korean Med Sci. 2009;24(4):695-700. doi: 10.3346/jkms.2009.24.4.695.

Dan S, Aditya P, Banerjee P, Bal C, Roy H, Banerjee I. Effect of chronic kidney disease on serum resistin level. Niger J Clin Pract. 2014 Nov-Dec;17(6):735-8. doi: 10.4103/1119-3077.144387.

Ellington A, Malik A, Klee G, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007;50:708-14. doi: 10.1161/HYPERTENSIONAHA.107.095257.

Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 2009 Nov;133(2):157-70. doi: 10.1016/j.clim.2009.07.013.

Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obesity Reviews. 2002 May;3(2):85-101. PMID: 12120424.

Lijnen HR. Role of fibrinolysis in obesity and thrombosis. Trombosis Research. 2009:123(4):S46-S49. doi: 10.1016/S0049-3848(09)70143-4.

Mänttäri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995 Oct;26(4):670-5.

Pontremoli R, Nicolella С, Viazzi F, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens. 1998 Apr;11(4 Pt 1):430-8. PMID: 9607381.

Mulè G, Nardi E, Cottone S, еt al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med. 2005 Jun;257(6):503-13. doi: 10.1111/j.1365-2796.2005.01493.x.




DOI: https://doi.org/10.22141/2307-1257.6.2.2017.102785

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru